The expression of mir-126 associated with clinicopathologic features In gastric carcinoma

Objective: With gene chip technology screening and reference to foreign research reports, we have determined to research the target gene miR-126.We detected the expression of miR-126 in gastric cancer tissues and their non-tumorous control .We also studied the correlation between the expression of miR-126 and clinicopathologicall Preliminary exploration of miR-126 in gastric cancer development, as well as potential tumor markers. Methods: 100 cases of fresh gastric carcinoma and adjacent normal tissue specimens were selected from gastric cancer radical resection, using the Trizol method to extract total RNA, and poly-A tail, anti-transcribed into cDNA, and then applied real-time fluorescence quantitative polymerase chain reaction (real-time PCR). Determination we initially selected gastric carcinoma Ct values of miR-126 and miR-126 Ct value, then the corresponding adjacent normal tissue. The 2 -△△Ct calculation method analysis of the measured Ct values were compared between gastric carcinoma cancer and adjacent normal tissues for the mi-R126 relative differences. Finally, we used statistical methods to contact clinicopathological parameters and miR-126 expression level in gastric cancer tissue. Results: We found that in the experimental group: miR-126 expression level in the gastric carcinoma group was significantly lower than the control group: namely the adjacent normal tissue group (P <0.001). From medical statistical analysis, miR-126 in gastric cancer tissues was significantly reduced, and the expression level had no correlation with gender, age, histological type, degree of differentiation of gastric cancer cells, lymph node metastasis, depth of invasion and UICC stage (P> 0.05). Conclusion: In gastric cancer tissues, the expression of miR-126 was significantly lower than in adjacent normal tissues. MiR-126 may become a potential biological tumor marker. This can provide a reliable basis for the early detection, early diagnosis, individualized treatment and prognosis, monitoring recurrence for patients with gastric cancer.